Chinese Journal of Respiratory and Critical Care Medicine
Supervisor：Ministry of Education of the People's Republic of ChinaSponsor：West China Medical Center & West China Hospital, Sichuan University Editor-in-chief：LIN Jiangtao / LIU Chuntao Publishing period：
Monthly
ISSN：1671-6205CN：51-1631/R
Citation：沈凌, 夏俊波, 王利民. 快速生長的肺巨細胞癌一例. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(2): 186-188. doi: 10.7507/1671-6205.201805017Copy
Copyright ? the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved
1.
Attanoos RL, Papagiannis A, Suttinont P, et al. Pulmonary giant cell carcinoma: pathological entity or morphological phenotype?. Histopathology, 1998, 32(3): 225-234.
Li X, Zhang ZH, Liu JH, et al. Molecular features of giant-cell carcinoma of the lung: a case report and literature review. Onco Targets Ther, 2018, 11: 751-756.
5.
Laforga JB. Giant cell carcinoma of the lung. Report of a case with cytohistologic and clinical correlation. Acta Cytologica, 1999, 43(2): 263-267.
6.
Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol, 2013, 8(12): 1574-1577.
7.
Leone A, Graziano P, Gasbarra R, et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer, 2011, 128(3): 732-735.
8.
Tamura Y, Fujiwara Y, Yamamoto N, et al. Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Res Notes, 2015, 8: 800.
9.
Weng SS, Cao Y, Tang XJ, et al. Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. Oncotarget, 2017, 8(15): 25323-25333.
10.
Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol, 2009, 39(4): 267-270.
11.
Weissferdt A, Moran CA. Primary giant cell carcinomas of the lung: a clinicopathological and immunohistochemical analysis of seven cases. Histopathology, 2016, 68(5): 680-685.
4. Li X, Zhang ZH, Liu JH, et al. Molecular features of giant-cell carcinoma of the lung: a case report and literature review. Onco Targets Ther, 2018, 11: 751-756.
5. Laforga JB. Giant cell carcinoma of the lung. Report of a case with cytohistologic and clinical correlation. Acta Cytologica, 1999, 43(2): 263-267.
6. Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol, 2013, 8(12): 1574-1577.
7. Leone A, Graziano P, Gasbarra R, et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer, 2011, 128(3): 732-735.
8. Tamura Y, Fujiwara Y, Yamamoto N, et al. Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Res Notes, 2015, 8: 800.
9. Weng SS, Cao Y, Tang XJ, et al. Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. Oncotarget, 2017, 8(15): 25323-25333.
10. Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol, 2009, 39(4): 267-270.
11. Weissferdt A, Moran CA. Primary giant cell carcinomas of the lung: a clinicopathological and immunohistochemical analysis of seven cases. Histopathology, 2016, 68(5): 680-685.
1/5
WeChat